newsfilter
← Latest News
GlobeNewswire·

MADRIGAL PHARMACEUTICALS, INC. INVESTIGATION: MDGL Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

  • Kirby McInerney LLP is investigating potential federal securities law violations & unlawful business practices by Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
  • Former Senior Vice President Dr. Michael Charlton filed a whistleblower complaint on October 9, 2026, alleging suppression of adverse liver-injury data & unreproducible efficacy results for the drug Rezdiffra.
  • Charlton claims he reported these issues to CEO Bill Sibold & CMO David Soergel, but was stripped of his title & forced to resign after being told to "stop looking."
  • Madrigal shares declined by 8.1% to close at $396.32 on November 3, 2026, following the disclosure of the complaint in the company's Form 10-Q.
  • No lawsuit has been filed yet as the investigation remains ongoing to determine if claims can be brought under federal securities laws.
  • Investors who acquired Madrigal securities are invited to contact Lauren Molinaro at Kirby McInerney LLP for a no-cost discussion regarding their rights.